Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Projecting future of mRNA-based COVID-19 vaccines remains difficult

By Brian Buntz | March 22, 2021

COVID-19 vaccineNanotechnology-enabled mRNA vaccines are having a banner year in 2021. That much is clear. But making sense of the long-term prospects of the nascent market for mRNA therapeutics remains challenging. 

Global Data projected that sales of leading nanotechnology-enabled mRNA vaccines could hit $17 billion this year in its January “The State of the Biopharmaceutical Industry” report.

But the sales of mRNA vaccines from mRNA vaccine leaders Pfizer and Moderna are on track to eclipse that figure. In February, Pfizer projected its COVID-19 vaccine sales for 2021 would be $15 billion. But additional orders for its vaccine, jointly developed with BioNTech, could boost that figure to at least $20 billion.  

Moderna anticipates that its vaccine 2021 sales will hit $18.4 billion. 

Drug companies are developing more than 150 mRNA-based candidates for a variety of therapeutic uses encompassing not just infectious diseases but areas such as genetic diseases and oncology, according to market research firm Roots Analysis. 

One potential wildcard for the market, however, is the duration of protection that mRNA vaccines offer against the novel coronavirus. 

At present, there is a dearth of human data on the subject. Transgenic mice injected with a single dose of mRNA vaccine had high levels of neutralizing antibodies for at least 6.5 months, according to a paper published in Nature. 

Recipients of Moderna’s mRNA-1273 vaccine had a strong immune response 90 days after receiving the second dose. 

Moderna itself believes the vaccine will provide immunity for at least one year. 

While an array of mRNA-based therapeutics is now in development, COVID-19 vaccines will likely make up the lion’s share of the market for some time. If mRNA-based vaccines offer long-lasting protection against COVID-19, sales could drop off starting in 2022. 

One factor that could influence the market as regions such as the U.S. and Europe have substantial rates of vaccine hesitancy is the potential for vaccine mandates. The travel industry could see a “soft mandate” for vaccination, according to Chad Nielsen, director of infection control at the University of Florida College of Medicine, in a call with UBS analysts. Travel guidelines encouraging vaccination could fuel demand for vaccines in general. Firmer mandates are likely in settings such as hospitals, cruise ships and possibly universities. Employers outside of healthcare are less likely to mandate vaccinations, Nielsen said.

As the pandemic wanes, however, mRNA vaccine producers may hike pricing. Pfizer exec Frank D’Amelio recently stated that the company may raise prices on its COVID-19 vaccine in a post-pandemic state.

Global Data projected that combined sales for Pfizer and Moderna mRNA vaccines would be approximately $5 billion in 2022, growing steadily thereafter. 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

institut pasteur dakar IPD African Union vaccine investment
African Union vaccine initiative receives $45M
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
This image shows the Moderna logo.
Moderna resizes its manufacturing footprint for a post-pandemic era
This is the logo of Pfizer.
Pfizer to close Durham and Morrisville, North Carolina facilities amid major restructuring effort
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE